Cabaletta Bio

Cabaletta Bio

Edit info

  • Founded: 2017
  • Location: Philadelphia, PA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Mucosal pemphigus vulgaris
  • Drug types: RAR, IMM, DRM, MUS, NEU, GEN, NPH
  • Lead product: DSG3-CAART
  • Funding: $100M stock May 2023; $75M IPO Oct 2019; $50M B Jan 2019; $38M Nov 2018


cabalettabio.com

linkedin.com

job board


Business:

Chimeric Auto Antibody Receptors

Drug notes:

MuSK-CAART Clin1 myasthenia gravis; PLA2R-CAART Clin0 membranous nephropathy; CABA-201 3 efforts Clin0 SLE, undisclosed; DSG3/1-CAART RD mucocutaneous pemphigus vulgaris

About:

Cabaletta Bio is developing T cell therapies for patients with B cell-mediated autoimmune diseases. Engineered T cell therapy takes advantage of T cell’s natural cell-killing capabilities and redirects their specificity to disease-causing cells by inserting a gene encoding a specific receptor. Known as chimeric antigen receptor (CAR) T cells, this approach has shown much success in cancer treatment. Cabaletta is encompassing CAR T cells for Autoimmunity (CARTA) which they hope to apply to many B cell-mediated autoimmune diseases. Cabaletta’s lead candidate in preclinical stages, CABA-201, is a fully human CD19 CARTA approach which has the potential to eliminate disease-causing B cells and allow for healthy B cell repopulation.

Cabaletta Bio
Associate Director/Director, Clinical Program Mana...
Philadelphia, PA|Not provided
Apply
Cabaletta Bio
Associate Director / Director, Clinical Scientist
All, All|Not provided
Cabaletta Bio
Supply Chain Associate
Philadelphia, Pennsylvania|Not provided
Cabaletta Bio
Associate Director/Director, Network Planning
Philadelphia, Pennsylvania|Not provided
Cabaletta Bio
Director / Sr. Director, Project Management – Tech...
Philadelphia, Pennsylvania|Not provided


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com